Effect of cumulative dose of brentuximab vedotin maintenance in relapsed/refractory classical Hodgkin lymphoma after autologous stem cell transplant: an analysis of real-world outcomes

Charlotte B. Wagner, Ken Boucher, Adrienne Nedved, Ivana N. Micallef, Sanjal Desai, Haris Hatic, 4 Gaurav Goyal, 4 Erin Zacholski, 5 Amanda Fegley, 5 Audrey M. Sigmund, 6 David A. Bond, 6 Courtney Samuels,⁷ Manali K. Kamdar,⁷ Sheeba Ba Aqeel,⁸ Pallawi Torka,⁸ Kira MacDougall,⁹ Azra Borogovac, ^{9°} Sridevi Rajeeve, ¹⁰ Suchitra Sundaram, ¹⁰ Kalub Fedak, ¹¹ Dipenkumar Modi, ¹¹ Elizabeth Travers,¹² Sabarish Ayyappan,¹³ Nitin Chilakamarri,¹⁴ Elizabeth A. Brem,¹⁴ Daniel A. Ermann,¹ Lindsey A. Fitzgerald, Boyu Hu, Deborah M. Stephens and Harsh Shah

¹University of Utah Huntsman Cancer Institute, Salt Lake City, UT; ²Mayo Clinic, Rochester, MS; ³University of Minnesota, Twin Cities of Minneapolis and Saint Paul, MS; ⁴University of Alabama Medicine, Birmingham, AL; ⁵Virginia Commonwealth University Health, Richmond, VI; ⁶The Ohio State University, Columbus, OH: 7University of Colorado Cancer Center, Aurora, CO: 8Roswell Park Comprehensive Cancer Center, Buffalo, NY; 9University of Oklahoma Health Sciences Center, Oklahoma, OH; ¹⁰Tisch Cancer Institute at Mount Sinai, New York, NY; ¹¹Karmanos Cancer Institute, Detroid, MI; 12 University of Kentucky HealthCare, Lexington, KY; 13 University of Iowa Hospitals and Clinics, Iowa City, IA and 14University of California, Irvine, CA, USA

°Current address: City of Hope Medical Center, Duarte, CA, USA

Correspondence: H. Shah harsh.shah@hci.utah.edu


January 19, 2023. Received: April 19, 2023. Accepted: April 27, 2023. Early view:

https://doi.org/10.3324/haematol.2023.282780

©2023 Ferrata Storti Foundation Published under a CC-BY license 🙃 🛈



Supplemental Figure 1: Time Independent Analysis for Progression Free Survival based on total cumulative dose



76-100%	39	32	17	1
51-75%	33	25	11	1
1-50%	46	26	7	0